Table 3. Previous studies on eperisone-induced ADRs including anaphylaxis.
| Age (year)/sex | Clinical manifestations | Provocation test | SPT | IDT | BAT | Patch test | Reference |
|---|---|---|---|---|---|---|---|
| 64/F | Anaphylaxis (urticaria, throat swelling, and loss of consciousness) | Pos | Neg | ND | Neg | ND | Miki et al.11 |
| 70/F | Anaphylaxis (urticaria and shock) | Pos | Neg (10 mg/mL) | Pos (10 mg/mL) | ND | ND | Kim et al.15 |
| 63/F | Anaphylaxis (urticaria, dyspnea, dysphagia, and chest pain) | Pos | ND | ND | ND | ND | Kang et al.1 |
| 58/M | Anaphylaxis (urticaria, shock, and loss of consciousness) | Pos* | ND | ND | ND | ND | Kang et al.1 |
| 58/M | Anaphylaxis (urticaria, dyspnea, and facial edema) | Pos | ND | ND | ND | ND | Kang et al.1 |
| 54/F | Anaphylaxis (urticaria, angioedema, dyspnea, shock, and dizziness) | ND | Neg | Neg | ND | ND | Hur et al.16 |
| 62/F | Anaphylaxis (dyspnea and angioedema) | ND | Neg | Neg | ND | ND | Hur et al.16 |
| 23/M | Drug eruption | Pos | NA | NA | NA | NA | Ueno and Kawana.22 |
| 30/M | Severe maculopapular rash | ND | ND | ND | ND | ND | Balaraddiyavar et al.23 |
| 42/F | Fixed drug eruption | Pos | ND | ND | ND | ND | Choonhakarn24 |
| 69/F | Acute generalized exanthematous pustulosis | ND | ND | ND | ND | Pos | Yamamoto et al.25 |
ADR, adverse drug reaction; M, male; F, female; SPT, skin prick test; IDT, intradermal test; BAT, basophil activation test; Neg, negative reaction; Pos, positive reaction; ND, not done; NA, not available (published in Japanese except abstract).
*Confirmed by history: 3 times re-challenge.